Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era

Annals of Hematology
Azim JalaliEliza A Hawkes

Abstract

Approximately 560 new cases of Hodgkin lymphoma (HL) are diagnosed annually in Australia. Standard first-line therapy is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). It is unknown how survival outcomes in patients receiving ABVD in current clinical practice, with routine positron emission tomography (PET) imaging and modern supportive measures, compare with results from published trials. This is a retrospective multi-centre study of patients with previously untreated HL between November 1999 and December 2014 receiving ABVD induction. Baseline characteristics, treatment details, toxicity and outcome data were collected from hospital records. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), response to treatment and toxicity. One hundred and eighty-nine eligible patients were identified. Median age was 32 years (range 17-79). Nodular-sclerosing HL was the most common subtype (78 %), 44 % had B symptoms and 11 % had marrow involvement. Median number of cycles of ABVD administered was 6 (range 3-8). Eighteen patients (11 %) had dose delay, 21 (13 %) had dose reductions and 11 (8 %) had both. The ORR, defined predominantly by PET s...Continue Reading

References

Mar 1, 1982·Cancer Treatment Reviews·G Bonadonna, A Santoro
Jun 13, 2003·The New England Journal of Medicine·Volker DiehlUNKNOWN German Hodgkin's Lymphoma Study Group
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo G GobbiUNKNOWN Intergruppo Italiano Linfomi
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J HoskinPeter W M Johnson
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George P CanellosAnn S LaCasce
Sep 8, 2010·The New England Journal of Medicine·Andreas EngertVolker Diehl
Jul 22, 2011·The New England Journal of Medicine·Simonetta VivianiUNKNOWN Intergruppo Italiano Linfomi
Dec 14, 2011·The New England Journal of Medicine·Ralph M MeyerUNKNOWN Eastern Cooperative Oncology Group
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bastian von TresckowAndreas Engert
Feb 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas Younes
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alden A MocciaLaurie H Sehn
May 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N MounierUNKNOWN Lymphoma Study Association (LYSA)
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 1, 2015·Seminars in Cancer Biology·Eri Matsuki, Anas Younes
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz HaverkampBastian von Tresckow
Dec 30, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco MerliMassimo Federico

❮ Previous
Next ❯

Citations

Nov 4, 2016·Annals of Hematology·Hugo J A Adams, Thomas C Kwee
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eliza A HawkesAndrew Grigg
Jul 15, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Hugo J A Adams, Thomas C Kwee
Sep 19, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Graça M DoresLindsay M Morton
Jul 15, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Elif HindiéNoël Milpied
Dec 28, 2016·British Journal of Haematology·Hugo J A Adams, Thomas C Kwee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.